Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Lu AF27139 是一种有效的选择性 P2X7 受体拮抗剂(人和大鼠的 IC50 分别为 12 和 2.4 nM,小鼠、人和大鼠的 Ki 分别为 22、54 和 13 nM)。 Lu AF27139 可用于中枢神经系统疾病研究。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 928 | 现货 | ||
5 mg | ¥ 2,260 | 现货 | ||
10 mg | ¥ 3,730 | 现货 | ||
25 mg | ¥ 5,910 | 现货 | ||
50 mg | ¥ 8,330 | 现货 | ||
100 mg | ¥ 11,200 | 现货 | ||
500 mg | ¥ 22,500 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 2,350 | 现货 |
产品描述 | Lu AF27139 is an effective and selective antagonist of P2X7 receptor (IC50s of 12 and 2.4 nM for human and rat, Kis of 22, 54, and 13 nM for mouse, human, and rat, respectively). Lu AF27139 can be used in CNS diseases studies. |
靶点活性 | P2X7:12 nM (human), P2X7:2.4 nM (human), P2X7:22 nM (mouse), P2X7:54 nM (human) |
体外活性 |
Lu AF27139 (100 nM) inhibits 300 μM BzATPinduced current in primary rat microglia with 80% inhibition occurring at a 100 nM dose. Lu AF27139 inhibits LPS-primed and BzATP-induced IL-1β release from THP-1 cells with an IC50 of 38 ± 2.5 nM. Lu AF27139 concentration-dependently blocks IL-1β release in rat and mouse primary cortical microglia primed with LPS and induces with 1 mM BzATP with IC50’s of 38 ± 19 nM in rat and 26 ± 6 nM in mice. Lu AF27139 (10-200 nM) inhibits 100 μM BzATP-induced current in HEK293 cells stably transfected with the rat P2X7R in a dose response manner with an IC50 of 66 nM[1]. |
体内活性 | In male Sprague−Dawley rats and male C57BL mice, Lu AF27139 (p.o.; 3, 10, and 100 mg/kg) reduces intracerebroventricular administered LPS-primed and BzATP-triggered IL-1β release in the frontal cortex[1]. |
分子量 | 497.92 |
分子式 | C21H19ClF3N5O2S |
CAS No. | 2097117-06-9 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 120 mg/mL (241.00 mM), Sonication is recommended.
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.0084 mL | 10.0418 mL | 20.0835 mL | 50.2089 mL |
5 mM | 0.4017 mL | 2.0084 mL | 4.0167 mL | 10.0418 mL | |
10 mM | 0.2008 mL | 1.0042 mL | 2.0084 mL | 5.0209 mL | |
20 mM | 0.1004 mL | 0.5021 mL | 1.0042 mL | 2.5104 mL | |
50 mM | 0.0402 mL | 0.2008 mL | 0.4017 mL | 1.0042 mL | |
100 mM | 0.0201 mL | 0.1004 mL | 0.2008 mL | 0.5021 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Lu AF27139 2097117-06-9 Membrane transporter/Ion channel Neuroscience P2X Receptor Inhibitor P2XRs Lu AF-27139 oral P2X7 Lu AF 27139 rodent-active CNS-penetrant CNS inhibit inhibitor